Skip to main content
SpringerLink
Log in

Hämostasestörungen bei onkologischen Patienten

Disorders of coagulation in oncological patients

  • Schwerpunkt: Onkologische Notfälle
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Onkologische Patienten erleiden häufig Hämostasestörungen, die sich als akutes thromboembolisches Ereignis, als disseminierte intravasale Gerinnungsaktivierung aber auch als hämorrhagische Diathese manifestieren können. In jedem Fall stellen diese Störungen eine ernste Herausforderung dar, die mit erhöhter Morbidität und Mortalität einhergehen und häufig ein interdisziplinäres Vorgehen verlangen. In diesem Artikel werden die tumorassoziierte Thrombophilie, die disseminierte intravasale Gerinnungsaktivierung als prokoagulatorische Störungen sowie das erworbene Von Willebrand-Syndrom und die Thrombozytopenie als typische hämorrhagische Diathesen onkologischer Patienten hinsichtlich Pathophysiologie, Diagnostik und Therapie dargestellt und diskutiert.

Abstract

Patients with malignancies often experience acute disorders of coagulation. They may manifest as thromboembolism, disseminated intravascular coagulation or a tendency to bleed. Either disorder carries a high rate of complications and a difficult task in diagnosing and treating them. Some complications typical for patients with malignancies are discussed. Among these are tumor associated thrombophilia, acquired von Willebrand’s disease, and thrombocytopenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Rickles FR, Levine MN (2001) Epidemiology of thrombosis in cancer. Acta Haematol 106: 6–12

    CAS  PubMed  Google Scholar 

  2. Edwards RL, Silver J, Rickles FR (1993) Human tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 69: 205–213

    CAS  PubMed  Google Scholar 

  3. Donati MB, Falanga A, Consonni R et al. (1990) Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 64: 11–16

    CAS  PubMed  Google Scholar 

  4. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, Rimm AA (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78: 285–291

    Google Scholar 

  5. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124 [Suppl]: 58S–68S

    CAS  PubMed  Google Scholar 

  6. Kwaan HC, Parmar S, Wang J (2003) Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost 29: 283–290

    CAS  PubMed  Google Scholar 

  7. Carroll VA, Binder BR (1999) The role of the plasminogen activation system in cancer. Semin Thromb Hemost 25: 183–197

    CAS  PubMed  Google Scholar 

  8. Nicolaides AN, Breddin HK, Fareed J et al.; Cardiovascular Disease Educational and Research Trust and the International Union of Angiology (2001) Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 20: 1–37

    Google Scholar 

  9. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930

    CAS  PubMed  Google Scholar 

  10. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346: 975–980

    Article  CAS  PubMed  Google Scholar 

  11. Bern MM, Lokich JJ, Wallach SR et al. (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112: 423–428

    CAS  PubMed  Google Scholar 

  12. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75: 251–253

    CAS  PubMed  Google Scholar 

  13. Meier CR, Jick H (1998) Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45: 608–612

    Google Scholar 

  14. Ornstein DL, Zacharski LR (2000) Cancer, thrombosis, and anticoagulants. Curr Opin Pulm Med 6: 301–308

    CAS  PubMed  Google Scholar 

  15. Prandoni P, Lensing AW, Piccioli A et al. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484–3488

    CAS  PubMed  Google Scholar 

  16. Levine MN, Lee AY, Kakkar AK (2003) From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J Thromb Haemost 1: 1456–1463

    CAS  PubMed  Google Scholar 

  17. Meyer G, Marjanovic Z, Valcke J et al. (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162: 1729–1735

    Article  CAS  PubMed  Google Scholar 

  18. Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR (1999) Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82: 947–952

    CAS  PubMed  Google Scholar 

  19. Gross PL, Aird WC (2000) The endothelium and thrombosis. Semin Thromb Hemost 26: 463–478

    CAS  PubMed  Google Scholar 

  20. Fisher CJ, Yan SB (2000) Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 28 [Suppl]: S49–56

    PubMed  Google Scholar 

  21. Kumar S, Pruthi RK, Nichols WL (2002) Acquired von Willebrand disease. Mayo Clin Proc 77: 181–187

    PubMed  Google Scholar 

  22. Mannucci PM (2004) Treatment of von Willebrand’s disease. N Engl J Med 351: 683–694

    CAS  PubMed  Google Scholar 

  23. Slichter SJ (2004) Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 18: 153–167

    PubMed  Google Scholar 

  24. Gaydos LA, Freireich EJ, Mantel N (1962) The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 266: 905–909

    CAS  PubMed  Google Scholar 

  25. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S (2002) Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 16: 34–45

    PubMed  Google Scholar 

  26. Goodnough LT (2003) Risks of blood transfusion. Crit Care Med 31 [Suppl]: S678–686

    Article  PubMed  Google Scholar 

  27. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M (2001) Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis ISTH Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86: 1327–1330

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Keine Angaben

Author information

Authors and Affiliations

  1. Abteilung Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule Hannover

    M. von Depka Prondzinski

  2. Abteilung Hämatologie, Hämostaseologie und Onkologie, Medizinische Hochschule, Feodor-Lynen-Straße 5, 30625, Hannover

    M. von Depka Prondzinski

Authors
  1. M. von Depka Prondzinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. von Depka Prondzinski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Depka Prondzinski, M. Hämostasestörungen bei onkologischen Patienten. Internist 46, 48–56 (2005). https://doi.org/10.1007/s00108-004-1329-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-004-1329-x

Schlüsselwörter

Keywords

Search

Navigation